{"title":"Unfurling the Potential of Antiviral Agents Aimed for RNA Virus Ailment.","authors":"Ritchu Babbar, Jasmeen Kaur, Kajalpreet Kaur, Swikriti, Vijay Dhondiram Vagh, Monika Sachdeva, Tapan Behl, Monica Gulati, Amin Gasmi","doi":"10.2174/0113894501336800250220051811","DOIUrl":"10.2174/0113894501336800250220051811","url":null,"abstract":"<p><p>Globally, high mortality is brought on by RNA viruses, which are linked to chronic human disorders. Viruses dominate the WHO's current ranking of the top 10 global health hazards, especially RNA viruses. RNA viruses, like HIV, SARS-CoV-2, and influenza, which are among the most prevalent and frequently encountered RNA viruses, use RNA as their genetic material, making them prone to quick changes. They adapt rapidly, complicating the body's immune responses. HIV, a significant retrovirus, infiltrates the immune system, causing AIDS by compromising defenses against infections. SARS-CoV-2, which led to COVID-19, sparked a worldwide pandemic with respiratory symptoms, emphasizing the need for research and therapeutic innovations. The COVID-19 pandemic has demonstrated the insufficiency of available resources in effectively addressing emerging viral infections. Influenza, a seasonal RNA virus, triggers flu outbreaks, impacting public health. Research is crucial to understanding how these viruses interact with hosts, aiding the development of effective treatments and strengthening our ability to face new viral threats. The most effective defenses against viral illnesses are virus-specific vaccinations and antiviral drugs. The present review emphasizes the prevalence of the three most pathogenic and widespread RNA viruses, namely HIV, influenza, and SARS-CoV2, their pathophysiology, and the current treatment with FDA-approved drugs. It also incorporates novel analogs that are under clinical trials as there is an urgent need for innovative antiviral medications, and enormous global efforts are required to find secure and efficient cures for these viral infections.</p>","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":"534-550"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Diabetic Wound Healing: Factors, Mechanisms, and Treatment Strategies Using Herbal Components.","authors":"Sejal Porwal, Rishabha Malviya, Sonali Sundram, Sathvik Belagodu Sridhar, Javedh Shareef","doi":"10.2174/0113894501354898241220075327","DOIUrl":"10.2174/0113894501354898241220075327","url":null,"abstract":"<p><p>Managing diabetic wounds is a significant challenge for healthcare professionals since severe complications and delayed recovery greatly impact the patients' quality of life. This article aimed to explore various factors affecting diabetic wound healing, the mechanism of wound healing, and potential natural products having wound healing capability. It focuses on mechanisms of action and the therapeutic effectiveness of the compounds employed in the management of diabetic wounds. The review discusses the function of nutrition in wound healing, emphasizing the significance of consuming adequate amounts of protein, energy, lipids, amino acids, vitamins, minerals, and water to promote healing. Several herbs, including <i>Rosmarinus officinalis, Carica papaya, Aloe vera, Annona squamosa</i>, and <i>Punica granatum</i>, are being tested for wound healing qualities in diabetes circumstances. These plants have a variety of modes of action, including antioxidant, anti-inflammatory, antibacterial, and immunomodulatory activities that help to speed up wound healing, stimulate collagen formation, and promote tissue regeneration. The variety of action mechanisms seen in natural products, especially in plants, offers hope for the treatment of diabetic wounds. It may also be possible to improve healing results and the quality of life of diabetes individuals with chronic wounds by including these herbal treatments in wound care programs.</p>","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":"367-381"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current drug targetsPub Date : 2024-09-18DOI: 10.2174/0113894501333936240801053620
Wanyu Tang, Yalong Dang
{"title":"In Vivo Models of Steroid-Induced Intraocular Hypertension","authors":"Wanyu Tang, Yalong Dang","doi":"10.2174/0113894501333936240801053620","DOIUrl":"https://doi.org/10.2174/0113894501333936240801053620","url":null,"abstract":"Corticosteroids are widely utilized for their anti-inflammatory and immunosuppressive properties but often lead to ocular complications, including ocular hypertension. If untreated, ocular hypertension can progress to optic nerve atrophy and eventually result in steroid-induced glaucoma, which poses a risk of irreversible visual damage. Approximately 40% of individuals experience increased intraocular pressure after steroid use, and around 6% develop glaucoma. Although steroid-induced glaucoma is usually temporary and reversible if the treatment duration is under a year, prolonged exposure can cause permanent vision impairment. The pathogenesis of steroid-induced glaucoma is suggested to arise from increased outflow resistance of aqueous humor, primarily due to decreased expression of matrix metalloproteinases. This deficiency promotes the deposition of extracellular matrix and the dysfunction of trabecular meshwork cells. Additionally, modifications in the actin cytoskeleton increase the stiffness and alter the morphology of trabecular meshwork, further impeding aqueous humor outflow. Molecular changes, such as elevated expression of the MYOC gene, have also been implicated in restricting aqueous outflow. Various animal models, including rats, mice, primates, rabbits, cattle, sheep, cats, and dogs, have been developed to study steroid-induced glaucoma. These models exhibit pathological, pathophysiological, and molecular similarities to human disease, making them valuable for research. This review aims to summarize common animal models of steroid-induced ocular hypertension, discussing their advantages and limitations. The goal is to help researchers select appropriate models for future studies, thereby advancing the understanding of disease mechanisms and developing preventive strategies.","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":"189 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142268327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current drug targetsPub Date : 2024-08-20DOI: 10.2174/0113894501297697240805103744
Menghan Zhu, Dongxia Qi, Dongliang Chen, Wenchong Ye, Xiaoyang Wang, Chunmei Wang, Wen Zhou, Bin Zhou, Juan Li, Keyu Zhang
{"title":"Joint Screening and Identification of Potential Targets of Nitazoxanide by Affinity Chromatography and Label-Free Techniques.","authors":"Menghan Zhu, Dongxia Qi, Dongliang Chen, Wenchong Ye, Xiaoyang Wang, Chunmei Wang, Wen Zhou, Bin Zhou, Juan Li, Keyu Zhang","doi":"10.2174/0113894501297697240805103744","DOIUrl":"https://doi.org/10.2174/0113894501297697240805103744","url":null,"abstract":"<p><strong>Background: </strong>Nitazoxanide not only exhibits a broad spectrum of activities against various pathogens infecting animals and humans but also induces cellular autophagy. Currently, the pattern of action and subcellular targets of nitazoxanide-induced cellular autophagy are still unclear.</p><p><strong>Methods: </strong>To identify potential targets of nitazoxanide in mammalian cells, we developed an af-finity chromatography system using tizoxanide, a deacetyl derivative of nitazoxanide, as a ligand. Affinity chromatography was performed using VERO cell extracts on tizoxanide-biotin, and the isolated binding proteins were identified by mass spectrometry. Candidate target proteins ob-tained using affinity chromatography were co-analysed with the drug affinity response target sta-bility method. Fluorescent probes obtained by coupling rhodamine B to nitazoxanide were used for intracellular localisation of the binding targets. Solvent-induced protein precipitation profiling and thermal proteome profiling were used to further validate the binding proteins.</p><p><strong>Results: </strong>The joint analysis of the drug affinity response target stability method and affinity chro-matography resulted in the screening of six possible candidate target proteins. Fluorescent probes localised the nitazoxanide-binding protein around the nuclear membrane. Molecular docking re-vealed that the binding proteins mainly formed hydrogen bonds with the nitro group of nitazoxa-nide. Solvent-induced protein precipitation profiling and thermal proteome profiling further vali-dated SEC61A, PSMD12, and PRKAG1 as potential target proteins of nitazoxanide.</p><p><strong>Conclusion: </strong>The data supports the idea that nitazoxanide is a multifunctional compound with multiple targets.</p>","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Trends on Nanomedicines as Novel therapeutics Approach in Targeting Nociceptors for Relieving Pain.","authors":"Trilochan Satapathy, Deepak Sahu, Himanshu Sahu, Ravindra Kumar Pandey, Shiv Shankar Shukla, Beena Gidwani","doi":"10.2174/0113894501315521240725065617","DOIUrl":"https://doi.org/10.2174/0113894501315521240725065617","url":null,"abstract":"<p><p>An important sensation that warns of potential harm to a specific area of the body is pain. The prevalence of pain-related conditions globally is a significant and growing public health issue. Chronic pain affects an estimated 1.5 billion people worldwide, with prevalence rates varying by region and demographic factors. Along with diabetes, cardiovascular disease, and cancer, pain is among the most frequent medical diseases. Opioid analgesics are the mainstay of current pain therapies, which are ineffective. Opioid addiction and its potentially fatal side effects necessitate novel treatment strategies. Nanotechnology offers potential advantages in pain management by enabling targeted drug delivery, which can enhance the efficacy and reduce the side effects of analgesic medications. Additionally, nanoparticles can be designed to release drugs in a controlled manner, improving pain relief duration and consistency. This approach also allows for the delivery of therapeutics across biological barriers, potentially enhancing treatment outcomes for chronic pain conditions. Nanomedicine enables sensitive and focused treatments with fewer side effects than existing clinical pain medicines; it is worth exploring as a potential solution to these problems. Furthermore, medication delivery systems that use nanomaterials are being used to treat pain. Whether it's the distribution of a single medication or a combination of therapies, this review seeks to summarise the ways in which drug delivery systems based on nanomaterials can be utilised to successfully treat and alleviate pain. For the purpose of writing this paper, we consulted several online libraries, including Pubmed, Science Direct, Pubmed Prime, and the Cochrane Library, to gather fresh and up-to-date material. This overview delves into the ins and outs of pain's pathophysiology, the present state of pain treatment, potential new pain treatment targets, and the various initiatives that have been launched and are still in the works to address pain with nanotechnology. Recent developments in nanomaterials-based scavenging, gene therapy for pain aetiology, and nanoparticle-based medicine delivery for side effect reduction are highlighted. Analgesics have been further covered in our discussion on FDA-approved pharmaceuticals and clinical advancements.</p>","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141981937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current drug targetsPub Date : 2024-08-08DOI: 10.2174/0113894501313365240722100902
Fariya Khan, Mohsin Vahid Khan, Ajay Kumar, Salman Akhtar
{"title":"Recent Advances in the Development of Alpha-Glucosidase and Alpha-Amylase Inhibitors in Type 2 Diabetes Management: Insights from In silico to In vitro Studies.","authors":"Fariya Khan, Mohsin Vahid Khan, Ajay Kumar, Salman Akhtar","doi":"10.2174/0113894501313365240722100902","DOIUrl":"https://doi.org/10.2174/0113894501313365240722100902","url":null,"abstract":"<p><p>Diabetes is a metabolic disorder caused by high glucose levels, leading to serious threats such as diabetic neuropathy and cardiovascular diseases. One of the most reliable measures for controlling postprandial hyperglycemia is to reduce the glucose level by inhibiting enzymes in the digestive system, such as Alpha-Glucosidase and Alpha-Amylase. Here, we have investigated the use of inhibitors to inhibit carbohydrate metabolism in order to restrict glucose levels in diabetic patients. Acarbose, Voglibose, and Miglitol are three inhibitors approved by the FDA that efficiently inhibit these two enzymes and thereby minimising hyperglycemia but are al-so significantly helpful in reducing the risk of cardiovascular effects. We also provide insight into the other known inhibitors currently available in the market. The adverse effects associated with other inhibitors emphasise the demand for the latest in silico screening and in vitro validation in the development of potent inhibitors with greater efficacy and safety for the treatment of Type 2 diabetes. The recent findings suggest that Alpha-Glucosidase and Alpha-Amylase play a major role in carbohydrate metabolism and triggering the increase in glucose levels. This review pro-vides the latest scientific literature findings related to these two enzymes as well as the role of primary and secondary inhibitors as potential candidates. Moreover, this review elaborates the framework on the mechanism of action, different plant sources of extraction of these enzymes, as well as kinetic assay of inhibitors and their interaction that can be used in future prospects to de-velop potential leads to combat Type 2 diabetes.</p>","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141916271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current drug targetsPub Date : 2024-05-03DOI: 10.2174/0113894501281496231226070459
Iqra Subhan, Yasir Hasan Siddique
{"title":"Effect of Rotenone on the Neurodegeneration among Different Models","authors":"Iqra Subhan, Yasir Hasan Siddique","doi":"10.2174/0113894501281496231226070459","DOIUrl":"https://doi.org/10.2174/0113894501281496231226070459","url":null,"abstract":": Rotenone is a naturally occurring plant product used as an insecticide, pesticide and piscicide. It is lipophilic in nature and can cross the blood-brain barrier and induce the degeneration of neurons. It inhibits the mitochondrial respiratory chain complex I and stops the transfer of electrons. It induces ROS generation, which impairs mitochondrial activity. Rotenone is a toxic agent which causes the death of neurons. The present review describes the effect of rotenone on neurodegeneration with an emphasis on behavioral, pathological and neuropathological components carried out on various experimental models such as cell lines, Drosophila melanogaster, mice and rats.","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":"54 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140831910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current drug targetsPub Date : 2024-04-27DOI: 10.2174/0113894501301747240417103321
Wasan Alwahsh, Shariza Sahudin, Hatim Alkhatib, Mohammad F. Bostanudin, Mohammad Alwahsh
{"title":"Chitosan-Based Nanocarriers for Pulmonary and Intranasal Drug Delivery Systems: A Comprehensive Overview of their Applications","authors":"Wasan Alwahsh, Shariza Sahudin, Hatim Alkhatib, Mohammad F. Bostanudin, Mohammad Alwahsh","doi":"10.2174/0113894501301747240417103321","DOIUrl":"https://doi.org/10.2174/0113894501301747240417103321","url":null,"abstract":": The optimization of respiratory health is important, and one avenue for achieving this is through the application of both Pulmonary Drug Delivery System (PDDS) and Intranasal Delivery (IND). PDDS offers immediate delivery of medication to the respiratory system, providing advantages, such as sustained regional drug concentration, tunable drug release, extended duration of action, and enhanced patient compliance. IND, renowned for its non-invasive nature and swift onset of action, presents a promising path for advancement. Modern PDDS and IND utilize various polymers, among which Chitosan (CS) stands out. CS is a biocompatible and biodegradable polysaccharide with unique physicochemical properties, making it well-suited for medical and pharmaceutical applications. The multiple positively charged amino groups present in CS facilitate its interaction with negatively charged mucous membranes, allowing CS to adsorb easily onto the mucosal surface. In addition, CS-based nanocarriers have been an important topic of research. Polymeric Nanoparticles (NPs), liposomes, dendrimers, microspheres, nanoemulsions, Solid Lipid Nanoparticles (SLNs), carbon nanotubes, and modified effective targeting systems compete as important ways of increasing pulmonary drug delivery with chitosan. This review covers the latest findings on CS-based nanocarriers and their applications.","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":"28 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140810099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current drug targetsPub Date : 2024-04-09DOI: 10.2174/0113894501310201240403065930
Rui Zhang, Yalong Dang
{"title":"The Recent Advances in the Function and Mechanism of Caveolin-1 in Retinal Neovascularization","authors":"Rui Zhang, Yalong Dang","doi":"10.2174/0113894501310201240403065930","DOIUrl":"https://doi.org/10.2174/0113894501310201240403065930","url":null,"abstract":": Retinal neovascularization diseases have relatively high rates of evitable blindness. Abnormal retinal neovascularization is their main hallmark, which can damage the structure and function of the eye and lead to impaired vision. Caveolin-1 is a membrane protein that is expressed in many types of retinal cells and is involved in retinal neovascularization. This review presents a comprehensive analysis of global research on specific functions of caveolin-1 in retinal neovascularization. We believe that the mechanism of action of caveolin-1 might be related to the regulation of relevant signal pathways and looked ahead the application prospects of modulating caveolin- 1 in retinal neovascularization diseases.","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":"32 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140591980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}